Maziar Mike Doustdar, the head of Novo Nordisk's international business, said that the company will restrict the sales of its heavyweight weight loss drug Wegovy (trade name: Novo and Win) in China to avoid a surge of Chinese patients causing insufficient drug supply in other parts of the world.
诺和诺德：将限制司美格鲁肽在华销售
Novo Nordisk: Will restrict the sale of semaglutide in China
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.